Taysha Gene Therapies (TSHA) Other Operating Expenses (2020 - 2025)

Taysha Gene Therapies (TSHA) has 6 years of Other Operating Expenses data on file, last reported at $83.4 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses rose 28.31% year-over-year to $83.4 million; the trailing twelve-month figure through Mar 2026 stood at $83.4 million (up 19.42% YoY), and the FY2025 full-year result was $83.4 million, up 19.42% from the prior year.
• Other Operating Expenses improved to $83.4 million in Q4 2025, from $65.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $128.9 million in Q4 2021 to a low of $616000.0 in Q3 2023.
• A 5-year average of $57.2 million and a median of $65.0 million in 2024 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses plunged 71.75% in 2022 and jumped 685.39% in 2024, its largest moves.
• Tracing TSHA's Other Operating Expenses over 5 years: stood at $128.9 million in 2021, then sank by 71.75% to $36.4 million in 2022, then soared by 122.88% to $81.2 million in 2023, then declined by 19.92% to $65.0 million in 2024, then increased by 28.31% to $83.4 million in 2025.
• Business Quant data shows TSHA's Other Operating Expenses at $83.4 million in Q4 2025, $65.0 million in Q4 2024, and $4.8 million in Q3 2024.